XML 70 R55.htm IDEA: XBRL DOCUMENT v3.25.3
Note 11 - Segment Data - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Revenues (a): $ 60,737 $ 57,833 $ 120,280 $ 116,003
Total segment cost of revenues 23,406 22,378 46,010 43,299
Gross Profit (c) 37,331 35,455 74,270 72,704
Operating expense 32,607 31,947 66,482 63,616
Operating income 4,724 3,508 7,788 9,088
Nonoperating expense, net (2,725) 304 1,223 (1,371)
Non-cash GKE inventory step-up amortization     0 1,232
Nonoperating (income), net 2,725 (304) (1,223) 1,371
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]        
Revenues (a): [1] 60,737 57,833 120,280 116,003
Depreciation in cost of revenues 791 904 1,601 1,766
Amortization in cost of revenues 707 672 1,409 1,319
Other cost of revenues (b) [2] 21,908 20,348 43,000 38,982
Total segment cost of revenues 23,406 22,378 46,010 43,299
Gross Profit (c) [3] 37,331 35,455 74,270 72,704
Operating expense 32,607 31,947 66,482 63,616
Operating income 4,724 3,508 7,788 9,088
Nonoperating expense, net 2,725 (304)   1,371
Earnings before income taxes 1,999 3,812 9,011 7,717
Non-cash GKE inventory step-up amortization   454   1,232
Nonoperating (income), net (2,725) 304   (1,371)
Sterilization and Disinfection Control [Member] | Operating Segments [Member]        
Revenues (a): [1] 22,107 22,205 47,517 45,162
Depreciation in cost of revenues 461 374 911 793
Amortization in cost of revenues 140 134 279 245
Other cost of revenues (b) [2] 6,636 6,071 13,291 12,162
Total segment cost of revenues 7,237 7,033 14,481 14,432
Gross Profit (c) [3] 14,870 15,172 33,036 30,730
Non-cash GKE inventory step-up amortization   454   1,232
Biopharmaceutical Development [Member] | Operating Segments [Member]        
Revenues (a): [1] 13,920 11,867 25,406 23,875
Depreciation in cost of revenues 66 40 155 86
Amortization in cost of revenues 375 346 747 691
Other cost of revenues (b) [2] 5,350 4,314 10,069 7,972
Total segment cost of revenues 5,791 4,700 10,971 8,749
Gross Profit (c) [3] 8,129 7,167 14,435 15,126
Non-cash GKE inventory step-up amortization   0   0
Calibration Solutions [Member] | Operating Segments [Member]        
Revenues (a): [1] 13,570 12,262 25,920 24,063
Depreciation in cost of revenues 112 207 217 392
Amortization in cost of revenues 0 0 0 0
Other cost of revenues (b) [2] 5,223 4,845 10,426 9,219
Total segment cost of revenues 5,335 5,052 10,643 9,611
Gross Profit (c) [3] 8,235 7,210 15,277 14,452
Non-cash GKE inventory step-up amortization   0   0
Clinical Genomics [Member] | Operating Segments [Member]        
Revenues (a): [1] 11,140 11,499 21,437 22,903
Depreciation in cost of revenues 152 283 318 495
Amortization in cost of revenues 192 192 383 383
Other cost of revenues (b) [2] 4,699 5,118 9,214 9,629
Total segment cost of revenues 5,043 5,593 9,915 10,507
Gross Profit (c) [3] $ 6,097 5,906 $ 11,522 12,396
Non-cash GKE inventory step-up amortization   $ 0   $ 0
[1] Intersegment revenues are not significant and are eliminated to arrive at consolidated totals. Revenues as presented are consistent with GAAP measurement principles and our CODM's review of segment information.
[2] Other segment cost of revenues for each reportable segment includes product costs, personnel costs (including stock-based compensation), and other manufacturing and overhead costs necessary to produce and sell our products and services, excluding depreciation, amortization and any non-cash inventory step-up amortization expense.
[3] Gross profit as presented is consistent with GAAP measurement principles and our CODM's review of segment information.